SG Americas Securities LLC Sells 5,897 Shares of Jazz Pharmaceuticals PLC $JAZZ

SG Americas Securities LLC trimmed its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 62.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,548 shares of the specialty pharmaceutical company’s stock after selling 5,897 shares during the period. SG Americas Securities LLC’s holdings in Jazz Pharmaceuticals were worth $377,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Dimensional Fund Advisors LP raised its holdings in Jazz Pharmaceuticals by 14.4% during the first quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company’s stock worth $289,066,000 after acquiring an additional 293,360 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Jazz Pharmaceuticals by 4.7% during the 1st quarter. JPMorgan Chase & Co. now owns 1,662,042 shares of the specialty pharmaceutical company’s stock worth $206,343,000 after purchasing an additional 74,501 shares during the last quarter. Fuller & Thaler Asset Management Inc. raised its stake in shares of Jazz Pharmaceuticals by 41.7% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company’s stock worth $165,245,000 after purchasing an additional 391,660 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Jazz Pharmaceuticals by 1.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,171,755 shares of the specialty pharmaceutical company’s stock valued at $124,366,000 after buying an additional 16,757 shares during the last quarter. Finally, Swedbank AB boosted its holdings in shares of Jazz Pharmaceuticals by 10.0% in the 1st quarter. Swedbank AB now owns 1,102,143 shares of the specialty pharmaceutical company’s stock valued at $136,831,000 after buying an additional 100,211 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Trading Down 0.2%

Shares of JAZZ stock opened at $176.61 on Friday. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $182.99. The company has a market capitalization of $10.73 billion, a PE ratio of -26.24, a price-to-earnings-growth ratio of 8.49 and a beta of 0.29. The firm has a 50 day moving average price of $143.87 and a two-hundred day moving average price of $124.99. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. JPMorgan Chase & Co. dropped their price target on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a research report on Monday, October 27th. Robert W. Baird boosted their price objective on shares of Jazz Pharmaceuticals from $160.00 to $209.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 18th. Royal Bank Of Canada set a $194.00 target price on shares of Jazz Pharmaceuticals and gave the company an “outperform” rating in a research note on Monday, November 17th. Zacks Research upgraded Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, August 15th. Finally, Truist Financial upped their price objective on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a “buy” rating in a research note on Thursday, August 28th. Thirteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $195.67.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, CAO Patricia Carr sold 5,319 shares of the business’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $182.06, for a total value of $968,377.14. Following the completion of the sale, the chief accounting officer directly owned 7,012 shares in the company, valued at $1,276,604.72. The trade was a 43.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Robert Iannone sold 7,159 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $168.26, for a total value of $1,204,573.34. Following the transaction, the executive vice president owned 72,628 shares in the company, valued at $12,220,387.28. The trade was a 8.97% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 50,893 shares of company stock worth $8,559,699 in the last 90 days. Company insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.